OKYO Pharma (NASDAQ:OKYO) Announces Quarterly Earnings Results, Misses Expectations By $5.45 EPS

OKYO Pharma (NASDAQ:OKYO) announced its quarterly earnings results on Monday. The company reported ($5.53) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($5.45), FiscalAI reports.

OKYO Pharma Trading Down 2.9%

OKYO stock traded down $0.04 during trading on Monday, hitting $1.39. The company had a trading volume of 301,306 shares, compared to its average volume of 169,514. OKYO Pharma has a 52-week low of $1.34 and a 52-week high of $3.35. The company has a 50 day simple moving average of $1.59 and a 200-day simple moving average of $1.76.

Analysts Set New Price Targets

A number of analysts have recently weighed in on OKYO shares. HC Wainwright reduced their target price on shares of OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OKYO Pharma in a report on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.67.

Institutional Trading of OKYO Pharma

Several institutional investors and hedge funds have recently modified their holdings of OKYO. Citadel Advisors LLC bought a new position in OKYO Pharma in the third quarter worth approximately $31,000. XTX Topco Ltd bought a new stake in OKYO Pharma during the 4th quarter valued at $36,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of OKYO Pharma by 235.0% in the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after buying an additional 96,800 shares during the period. Institutional investors own 2.97% of the company’s stock.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.